ArticleInternational journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists2019
Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade).
Article in International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Impact of the microcystic, elongated, and fragmented invasion pattern on prognosis in endometrial carcinoma: a comprehensive meta-analysis.Frontiers in oncology · 2025Pooled it
- Evaluation of prognostic significance of lymphovascular space invasion in early stage endometrial cancer: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.Virchows Archiv : an international journal of pathology · 2021Guideline
- Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups.Archives of gynecology and obstetrics · 2020Pooled it
- Fertility-Sparing Treatment of Endometrial Cancer: Survey of Australian Practice.The Australian & New Zealand journal of obstetrics & gynaecology · 2026Article
- Article
- Decoding the 2023 FIGO Staging System in Endometrial Cancer: A Practical, Visually Guided Framework for Molecular Risk-Adapted Care Incorporating the 2025 Risk Group Update.Current oncology reports · 2026Review
- Impact of the 2023 FIGO staging system on risk stratification in endometrial cancer: a retrospective cohort study.World journal of surgical oncology · 2026Article
- Impact of Facility Volume on Therapy and Survival for Endometrial Cancer: A Retrospective Multicenter Study.Cancers · 2026Article
- Predictors of sentinel lymph node mapping failure in endometrial cancer: a retrospective multicenter study.Frontiers in oncology · 2026Article
- Pretreatment Pan-Immune-Inflammation Value and Corrected Prognostic Nutritional Index for 24-Month Recurrence Risk Stratification After Neoadjuvant Chemotherapy and Surgery in Stage III Endometrial Cancer.International journal of women's health · 2026Article
- Insights from the Pre-Molecular Era in Advanced Endometrial Cancer: Benchmarking Prognostic Indicators in High-Risk Tumours.Journal of clinical medicine · 2025Article
- Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer.Oncology and therapy · 2025Article
- Cyclin D1 expression predicts mismatch repair deficiency and correlates significantly with overall survival and recurrence free survival in endometrial carcinoma.Journal of molecular histology · 2025Article
- The Demographics and Outcomes of Women With Stage II Endometrial Cancer Diagnosed in Australia 2005-2007.The Australian & New Zealand journal of obstetrics & gynaecology · 2025Article
- Cancer of the corpus uteri: A 2025 update.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Review
- New histopathological and molecular findings in gynecological cancers.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Review
- The past, present, and future of FIGO staging of endometrial cancer.Journal of gynecologic oncology · 2025Review
- Comparative analysis of hysterectomy types and approaches on oncological survival in 2023 FIGO stage II endometrial carcinoma.BMC surgery · 2025Article
- A Radiomic-based model to predict the depth of myometrial invasion in endometrial cancer on ultrasound images.Scientific reports · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although endometrial carcinoma (EC) is generally considered to have a good prognosis, over 20% of women with EC die of their disease, with a projected increase in both incidence and mortality over the next few decades. The aim of accurate prognostication is to ensure that patients receive optimal treatment and are neither overtreated nor undertreated, thereby improving patient outcomes overall. Patients with EC can be categorized into prognostic risk groups based on clinicopathologic findings. Other than tumor type and grade, groupings and recommended management algorithms may take into account age, body mass index, stage, and presence of lymphovascular space invasion. The molecular classification of EC that has emerged from the Cancer Genome Atlas (TCGA) study provides additional, potentially superior, prognostic information to traditional histologic typing and grading. This classifier does not, however, replace clinicopathologic risk assessment based on parameters other than histotype and grade. It is envisaged that molecular and clinicopathologic prognostic grouping systems will work better together than either alone. Thus, while tumor typing and grading may be superseded by a classification based on underlying genomic abnormalities, accurate assessment of other pathologic parameters will continue to be key to patient management. These include those factors related to staging, such as depth of myometrial invasion, cervical, vaginal, serosal surface, adnexal and parametrial invasion, and those independent of stage such as lymphovascular space invasion. Other prognostic parameters will also be discussed. These recommendations were developed from the International Society of Gynecological Pathologists Endometrial Carcinoma project.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.